RxDoctor Payments Data

Chandrasekhara Punukollu, MD

Gastroenterology · Mount Pleasant, PANPI 1912014549

Payments from drug & device makers

$1,219in general payments, 2019–2025

Across 37 payments — averaging $32.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$470
  • Pfizer$141
  • Boston Scientific$116
  • Novo Nordisk$84
  • Regeneron Healthcare Solutions, Inc.$81
  • Madrigal Pharmaceuticals$78
  • plus $249 from 7 others

What the payments were for

  • Food & beverage$1,219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,219 in reported general payments places this provider in the 40th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$74,391
Medicare patients
356
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine47$32,130
LinzessLinaclotide43$28,237
CreonLipase/Protease/Amylase11$27,921
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates214$14,591
Pantoprazole Sodium739$9,243
Lubiprostone30$5,935
Omeprazole398$4,634
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg154$3,426
ClenpiqSod Picosulf/Mag Ox/Citric Ac19$3,162
Ursodiol18$3,131
Lansoprazole32$3,016
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,077
Famotidine164$1,772
Sucralfate35$1,183
Lactulose29$1,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$470$56,15854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Mount Pleasant

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →